Incidence, mortality and trends in Europe and worldwide; national and European registries and collaboration with eUROGEN, EURACAN, GLOBOCAN; environmental factors research; genetic dispositions — pan-European study and collaboration with TECAC.

Molecular aberrations and pathways in pathogenesis, tumor microenvironment and immune landscape, GCNIS biology, pathology classification including rare testicular tumors, reference centers, biobanking.

miR and their implementation in clinical practice, ctDNA, further biomarkers, omics studies.

Novel imaging techniques in diagnosis and prediction, virtual reality in preoperative surgical planning, small testicular mass management, robotic surgery, training centers and guidelines, collaboration with eUROGEN WS3.

Identification of novel therapeutic targets, clinical studies, novel treatment approaches, international multidisciplinary team set-up and scheduling, standards of care for specific subgroups of testicular tumor patients.

Fertility and its preservation, long-term genotoxic effects on male gametes, biomarkers for monitoring and potential consequences on offspring, prediction of hypogonadism, second malignancies, increased risk of cardiovascular and other diseases, psychological issues, existing EU projects.

Material — patient samples, cell lines, experimental models, technologies and know-how, databases, information handling and exchange, data sharing and data mining.

Research platforms — MaGIC, TECAC, ERN-eUROGEN, ERN-EURACAN; patient groups; further stakeholders — public institutions, commercial companies, pharmaceutical, biotechnological, others.

Care-providers in underrepresented countries training, young researchers' and residents' education and training, patients' and patient representatives' collaborations, public awareness, meetings, workshops, promotional activities and others.